NASDAQ · PHARMACEUTICAL PREPARATIONS · MID CAP
Lifecore Biomedical, Inc. LFCR
16 fiscal years on record · USD · FY2024 reported
SEC FILINGS ONLY
Revenue · FY2024
$128.9M
▲ 0.5% vs FY2023
EPS · FY24
$-1.27
Dividend / sh · FY24
—
Payout · FY24
—
ROE · FY24
-612.1%
Net margin · FY24
-30.0%
Dividend coverage
—
Advertisement
AdSense · Leaderboard 728×90320×100
Result
USD 128.9M
Revenue, FY2024 · full 16-year series below
Revenue
Net income
The company lost 30 cents on every revenue dollar this year.
Per share
USD -1.27
Diluted EPS, FY2024
EPS
The company pays no cash dividend.
Profitability
-612.1%
Return on equity, FY2024
ROE
Operating margin-13.4%
Net margin-30.0%
Return on assets-15.7%
Each USD of equity lost 612 cents this year.
Returned to shareholders
—
returned in FY2024 · dividends + net buybacks
Dividends paid—
Net buybacks—
Share of profit—
Consecutive raises—
Growth
−4.2% a year
revenue, compounded over five years
CAGR
3 yrs
5 yrs
10 yrs
15 yrs
Revenue
+5.0%
−4.2%
−13.3%
−4.0%
Compound annual rates per period — left blank where the series crosses a loss.
Share base
0.04B
Shares outstanding, FY2024
Change, 5 years+26.7%
Change, 10 years+37.2%
The share count grew 27% in five years — the same company, cut into more, smaller slices.
Advertisement
AdSense · Leaderboard 728×90300×250
Balance sheet
USD 239.3M
total assets, end of FY2024
Total assetsUSD 239.3M
EquityUSD 1.3M
CashUSD 8.3M
Gross debtUSD 133.9M
Net debtUSD 125.6M
Current ratio2.84×
Net debt stands at 9402% of equity.
History
16 fiscal years
Every figure from documents filed with the SEC · USD
Metric
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
2012
2011
2010
2009
Revenue $B
0.1
0.1
0.1
0.1
0.1
0.2
0.6
0.5
0.5
0.5
0.5
0.5
0.4
0.3
0.3
0.2
Operating income $B
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
0.0
0.0
0.0
−0.0
0.0
0.0
0.0
0.0
0.0
0.0
EBITDA $B
−0.0
−0.0
−0.0
0.0
0.0
−0.0
0.0
0.0
0.0
−0.0
0.0
0.0
0.0
0.0
0.0
0.0
Income tax $B
0.0
0.0
0.0
−0.0
−0.0
−0.0
0.0
−0.0
0.0
−0.0
0.0
0.0
0.0
0.0
0.0
−0.0
Net income $B
−0.0
0.0
−0.1
−0.1
−0.0
−0.0
0.0
0.0
0.0
−0.0
0.0
0.0
0.0
0.0
0.0
0.0
EPS, diluted $
−1.27
0.33
−3.32
−3.97
−1.10
−1.31
0.01
0.89
0.38
−0.43
0.50
0.71
0.85
0.49
0.15
0.15
Dividend / sh $
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
Payout %
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
ROE %
−612.1
339.1
−238.2
−80.6
−15.0
−15.3
0.2
10.4
4.8
−5.4
6.4
10.0
13.8
8.9
2.9
·
Shares out B
0.04
0.03
0.03
0.03
0.03
0.03
0.03
0.03
0.03
0.03
0.03
0.03
0.03
0.03
0.03
·
Slide the table for earlier years · "·" marks figures not disclosed in the filing for that year.
How we verifyAUDITED
62 of 62
checks passed before publication
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidity
Every figure was compared against the original statement: 0 failures and 0 presentation gaps.
What we don’t show
We’d rather say what’s missing than fill the gap with an estimate.
P/E rationeeds a market quote — not yet licensed
Market capitalizationneeds a market quote — not yet licensed
Dividend yieldneeds a market quote — not yet licensed
Price-to-bookneeds a market quote — not yet licensed